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Abstract
Objective—To compare the effects of combinatorial therapy with low-dose arginine and a
nitrogen scavenging agent (sodium phenylbutyrate) vs. monotherapy with high-dose arginine on
liver function tests in patients with argininosuccinic aciduria (ASA).
Study design—Twelve patients with ASA were enrolled in a double-blind, placebo-controlled,
cross-over study design. Subjects were randomized to receive either a low-dose of arginine
therapy (100 mg•kg−1•d−1) combined with sodium phenylbutyrate (500 mg•kg−1•d−1) (LDA arm)
or a high-dose of arginine alone (500 mg•kg−1•d−1) (HDA arm) for one week. At the end of one
week of therapy, liver function tests were assessed and metabolite fluxes were measured using a
multi-tracer stable isotope protocol.
Results—Plasma aspartate aminotransferase (AST), alanine aminotransferase (ALT), and
measures of synthetic functions of the liver were the primary outcomes. Subjects had significantly
increased levels of argininosuccinate (P <0.03) and AST levels (P<0.01) after treatment with high-
dose arginine. In the subset of subjects with elevated AST or ALT, treatment with high-dose of
arginine was associated with further increases in plasma levels of both aminotransferases.
Whereas subjects had increased arginine and citrulline flux with high-dose arginine therapy, the
glutamine flux was not different between the two treatment arms. The synthetic liver functions as
assessed by prothrombin time, INR, and coagulation factor levels were not different between the
HDA and LDA arms.
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Conclusions—Administering higher doses of arginine in subjects with ASA results in increases
in AST and ALT levels, especially in the subset of patients with elevated baseline
aminotransferases. Hence, low-dose arginine sufficient to normalize arginine levels in serum
combined with nitrogen scavenging therapy should be considered as a therapeutic option for
treatment of ASA in patients with elevations of hepatic aminotransferases.
Keywords
Rare disease clinical research; argininosuccinate lyase; argininosuccinic aciduria; arginine
therapy; hepatic disease
1. Introduction
The urea cycle is the principal mechanism for disposal of waste-nitrogen in mammals.
Primary and secondary defects of urea cycle enzymes or transporters result in urea cycle
disorders (UCDs), a group of inborn errors of hepatic metabolism that often result in life-
threatening hyperammonemia [1]. Argininosuccinic aciduria (ASA), caused by deficiency of
the enzyme argininosuccinate lyase (ASL), is the second most common UCD [1, 2]. In
addition to hyperammonemia, the classic feature observed in all UCDs, subjects with ASA
can develop chronic complications that include hepatic disease, neurocognitive deficiencies,
and hypertension [2–6]. Hepatic involvement ranging from asymptomatic hepatomegaly and
elevation of aspartate and alanine aminotransferases to liver fibrosis can occur even in
subjects without significant hyperammonemic episodes [2, 3, 7]. The pathogenesis of liver
involvement in ASA is presently unknown. However, the accumulation of argininosuccinate
upstream of the metabolic block, the deficiency of arginine and its metabolites downstream
of the block, or nitric oxide deficiency may have a role in causation of hepatic
complications.
Traditionally, subjects with ASA have been supplemented with high doses of arginine (400–
700 mg•kg−1•d−1) to replenish the arginine pool and to facilitate nitrogen excretion via
conversion to argininosuccinate [1]. While arginine supplementation prevents metabolic
decompensations, its effects on the chronic complications including hepatic disease is
unknown [8]. We hypothesized that if argininosuccinate is hepatotoxic, administering higher
doses of arginine for purposes of nitrogen excretion would lead to increased production of
argininosuccinate, thus resulting in increased hepatic injury. If this were to be true, diverting
nitrogen flux away from the urea cycle by the use of a nitrogen scavenging agent in
combination with a low-dose of arginine would lead to decreased generation of
argininosuccinate and reduced hepatic injury.
Here, we report a randomized, double-blind, placebo-controlled, cross-over trial evaluating
the effect of two treatment modalities i.e., a low-dose of arginine combined with sodium
phenylbutyrate (low-dose arginine or LDA arm) vs. a high-dose of arginine alone (high-dose
arginine, HDA arm) on liver function tests, nitrogen excretion and urea flux in subjects with
ASA.
2. Methods
This was a single center study conducted at Texas Children’s Hospital and Baylor College
of Medicine (BCM), Houston, TX, USA. The protocol was approved by the Institutional
Review Boards of BCM and the Urea Cycle Disorders Consortium. An independent data
monitoring and safety committee managed by the NIH Rare Disease Clinical Research
Network oversaw the conduct of the trial. Subjects with a confirmed diagnosis of ASA,
weight > 10 kg, and serum creatinine less than 1.5 mg/dL were included in the study.
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Participants were studied as inpatients where they were randomized to either the LDA or
HDA arms. In the LDA arm, subjects received a low-dose of arginine (100 mg•kg−1•d−1 if
weight < 20 kg, or 2 g/m2 of body surface area (BSA)/day if weight > 20 kg) combined with
sodium phenylbutyrate (500 mg•kg−1•d−1 if weight < 20 kg, or 10 g/m2 of BSA/day if
weight > 20 kg). In the HDA arm, they were administered a high-dose of arginine (500
mg•kg−1•d−1 if weight < 20 kg or 10 g/m2 of BSA/day if weight > 20 kg) with placebo
instead of sodium phenylbutyrate. The duration of each arm was seven days. On days six
and seven, study procedures were performed and subjects were discharged home. After a
median period of 54 (range 4–77) days, subjects were re-admitted and crossed over to the
alternative arm of the study (Figure 1A).
2.1 Study procedures
Subjects were maintained on a protein-restricted diet (0.6 g•kg−1•d−1) or their currently
recommended metabolic diet (Table 1) and were randomized to either arm of the study
according to standard procedures. On days six and seven, liver function tests, plasma amino
acids and serum chemistries were assayed using standard techniques in the CLIA certified
laboratory at TCH (Figure 1A). On day six, the subjects consumed two-thirds of their total
daily intake of protein as meals fed every two hours at 0, 2, 4, 6, and 8 hours. The remaining
one-third of the day’s protein intake was provided during dinner. At time 0, a baseline blood
sample was collected which was followed by primed-constant infusions of [5-15N]
glutamine (2 mg•kg−1;2 mg•kg−1•hr−1), [18O][13C]urea (1 mg•kg−1; 0.1 mg•kg−1•hr−1),
[1,2-13C2]arginine (0.69 mg•kg−1; 0.69 mg•kg−1 hr−1), and [5-13 C,4,4,5,5-D4]citrulline
(0.18 mg•kg−1; 0.18 mg•kg−1•hr−1). The priming dose was administered in 10 minutes
whereas the constant infusion continued for 8 hours. Blood samples for isotopic enrichment
were drawn at 0, 6, 7 and 7.5 hours of infusion. Primed-constant infusion of a metabolite
tracer (i.e. stable isotopic form of a metabolite) in the above-mentioned doses allows for
successful detection of isotopic enrichment and calculation of the flux of the respective
metabolite. These stable isotopes were chosen to measure the flux of arginine, citrulline,
glutamine, and urea. The isotope infusion protocol has been previously validated for
sensitivity in six control and three ASA subjects [9]. The entry rate of urea, arginine,
citrulline and glutamine were calculated from the isotopic dilution of the infused tracer at
plateau enrichment. The plasma phenylacetyl-glutamine (PAGN) was measured by high-
performance liquid chromatography at the diagnostic laboratories of Vanderbilt Medical
Center, Nashville, TN, USA.
2.2 Outcomes
The primary outcome measures were plasma aspartate aminotransferase (AST), alanine
aminotransferase (ALT), and synthetic function of the liver as assessed by prothrombin time
(PT), international normalized ratio (INR), partial thromboplastin time (PTT), and plasma
levels of coagulation factors I and IX. The exploratory endpoints were the plasma levels of
argininosuccinate, arginine and citrulline as well as the fluxes of arginine, citrulline and
urea.
2.3 Statistical Analysis
For calculation of sample size, we used the means and standard deviations (SD) for PT,
PTT, the primary outcome measures as follows, mean (SD): 15.7 (0.62) for PT and 32.8
(3.02) for PTT. Assuming r=0.5 between two measurements from the same subject, 12
subjects would provide a power of 0.8 to detect a 10% reduction in primary endpoints at an
alpha value of 0.05. The interval period between the two admissions did not allow for any
carry-over effect between the two treatment arms. However, we performed two-way
repeated measures ANOVA to test for 1) the effect of order of treatment, 2) the treatment,
and 3) the interaction between the two factors. The analysis did not show any significant
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effect of order of treatment on the primary endpoints. When the data were normally
distributed, a paired t-test was used for comparison while Wilcoxon Signed Rank Test was
used to compare non-normative data between the two arms. Regression analysis was
performed using generalized estimating equations (GEE) in order to account for repeated
measures on subjects. Partial η2 (analogous to r2) is reported as the proportion of variation
accounted for by the independent variable after accounting for subject. A Spearman rank
correlation was performed for calculation the correlation co-efficient.
3. Results
Twelve subjects (five males, seven females) were enrolled in the trial. Six subjects were
randomized to the LDA arm and six to the HDA arm as the initial treatment arm. One
subject was excluded from the analysis as he developed mild hyperammonemia on both
arms of the trial and could not complete the study procedures. The median age of the
subjects was 13.7 years (range 4.3–23.25). Only one subject had neonatal-onset disease. The
subject characteristics are summarized in Table 1.
The plasma PAGN levels were elevated in subjects on the LDA arm, whereas the plasma
arginine was significantly higher on the HDA arm. This is consistent with the physiological
effects of the treatments in the respective arms (Figure 1B). The plasma glutamine and
ammonia levels were normal and comparable in both arms implying that neither intervention
adversely affected the short-term nitrogen balance in steady-state and stable subjects (Figure
1C). The plasma levels of albumin, and prealbumin were normal and comparable in both
arms of the study (data not shown), suggesting that neither intervention adversely affected
nutritional status in the short-term.
3.1 Effects on metabolite flux and concentration
To understand the effects of the two treatments on the dynamic fluxes of metabolites, we
used primed-constant infusions of multiple stable isotope tracers. As expected, treatment
with the high-dose of arginine was associated with significantly increased fluxes of arginine
and citrulline (Figure 2A). The high-dose of arginine increased the urea flux, but the
glutamine flux, was similar in both arms, supporting that neither intervention adversely
affected nitrogen balance (Figure 2B). Treatment with the high-dose of arginine resulted in
higher plasma argininosuccinate levels (P=0.024; Figure 2C).
3.2 Effects on aspartate and alanine aminotransferases and hepatic synthetic function
The plasma AST levels were significantly higher (P=0.002) when subjects were treated with
the high-dose of arginine (Figure 3A, Table 2). A similar trend was observed in the plasma
ALT levels but this did not reach statistical significance (Figure 3A, Table 2). To assess the
correlation between the plasma levels of aminotransferases and argininosuccinate, we
conducted linear regression analysis. The analysis showed significant correlation (P<0.001)
between plasma argininosuccinate and aminotransferase levels (Figure 3B); however, this
result must be viewed with caution, as a single subject (100551) had a large influence. The
hepatic synthetic functions as assessed by PT, INR, PTT, factor I, and factor IX levels were
normal and similar in both treatment arms (Figure 4). In an effort to address a clinically
relevant question regarding the effects of high-dose arginine therapy in subjects with pre-
existing hepatic disease, we performed a stratified analysis of subjects with elevations of
alanine and aspartate aminotransferase levels. In the subset of patients with abnormal
aminotransferases on at least one arm of the study, treatment with combinatorial therapy
with low-dose of arginine and sodium phenylbutyrate resulted in statistically significant
decreases in both AST and ALT as compared to high-dose arginine (Figure 5)
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4. Discussion
Many subjects with ASA receive high doses of arginine supplementation (400–700 mg/kg/
day) as this therapy had been considered safe and efficacious [10]. However, recent
observations have shown that chronic complications such as hepatic dysfunction, cognitive
impairment, and hypertension can occur in spite of arginine therapy and the absence of
hyperammonemia [3, 4, 6, 11]. Long-term studies in ASA subjects identified through
newborn screening programs have not detected an improved outcome in subjects
supplemented with arginine as compared to those who were not [4, 11]. Recent evidence
shows that arginine supplementation in ASA does not correct the deficiency of one of its
downstream metabolites, nitric oxide (NO) [9]. It is presently unclear whether arginine
supplementation restores the other downstream metabolites of arginine. In addition, higher
doses of arginine would lead to increased generation of ASA which has been suggested to be
hepatotoxic. This raises an important question as to whether high-dose arginine therapy
should be used as the sole treatment for nitrogen excretion when there is the theoretical risk
of increased generation of argininosuccinate.
In this trial, we show that subjects with ASA had higher AST and ALT levels when treated
with a high-dose of arginine. In particular, subjects with elevations of AST and ALT had
significant increase in aminotransferases when treated with high-dose of arginine. While
serum aminotransferase levels are a sensitive indicator of hepatic cell injury, their elevations
can be found in conditions not involving the liver such as disorders of skeletal muscle [12–
14]. Our data cannot conclusively prove that the liver was the source for elevated levels of
elevated ALT and AST. However, none of the subjects had any clinical evidence suggestive
of skeletal muscle disease and hence it is not unreasonable to ascribe liver as the source of
the aminotransferases. The increase in the plasma aminotransferases correlated with
increases in argininosuccinate levels suggesting that argininosuccinate may have a role in
hepatic injury. Whereas the correlation data are interesting, they do not imply causality.
Establishing causality of argininosuccinate in pathogenesis of hepatic disease in ASA would
need detailed studies involving animal models. Hypomorphic models of ASL and
argininosuccinate synthase 1 (ASS1) deficiencies have been developed with the former
having significant hepatic dysfunction and the latter with no reported hepatic involvement
[9, 15]. Hence, a double knockout model with loss of both ASL and ASS1 may help dissect
the role of argininosuccinate in hepatic disease.
Our study did not show any discernible differences in the hepatic synthetic function between
the two treatment arms. We used coagulation factor levels and coagulation parameters as
measures of hepatic synthetic function since the treatment duration was short. While
coagulation parameters are sensitive indicators of decreased hepatic function, they are only
altered in the presence of significant hepatic injury. The lack of a sensitive marker for
assessment of hepatic synthetic reserve in milder forms of hepatocellular injury limits our
ability to understand whether the increase in serum aminotransferases translates into
decreased hepatic reserve. We have recently shown that ASL is required for NO production
at the level of individual tissues as well as the whole organism [9, 16]. Because the NO
deficiency in microvasculature may contribute to liver fibrosis, long-term hepatic injury may
be further modified by NO status.
Our study also showed that in the short-term, both treatment modalities were efficacious in
maintaining the nitrogen balance. The increase in urea flux in the HDA arm was largely due
to efficient conversion of arginine to urea. However, it is possible that the diversion of
nitrogen away from the urea cycle in the LDA arm by sodium phenylbutyrate may have also
contributed to the difference in the urea flux between the two treatment modalities.
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The duration of our study was for one week and the median plasma arginine level of the
subjects was in the normal ranges even with the dose of arginine being 100 mg•kg−1•d−1.
However, the dose of arginine required for maintaining the plasma arginine levels in the
normal ranges with chronic therapy is likely to differ in individual patients. The primary
goal of arginine therapy in ASA subjects is to prevent hyperammonemia and the minimal
dose needed to accomplish this while maintaining normal plasma levels of arginine should
be used. However, if a high-dose of arginine is being used for the sole purpose of nitrogen
excretion, especially in subjects with hepatic disease, lowering the dose of arginine and
addition of a nitrogen scavenger should be considered.
5. Conclusion
In summary, the pathogenesis of hepatic disease in ASA is likely multi-factorial, with
elevations of argininosuccinate being one important factor. Our results suggest that
administering high-dose of arginine in ASA subjects can result in abnormalities in the liver
function tests. Hence in subjects with preexisting hepatic disease, low-dose arginine
sufficient to normalize arginine levels in serum, combined with nitrogen scavenging therapy
should be considered as an alternative therapeutic option for chronic treatment. However, in
the context of acute hyperammonemia, intravenous infusion of high-dose arginine should
still be used because of its efficacy in clearing excess nitrogen in the form of ASA.
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Highlights
1. We describe the first investigator initiated randomized double-blind study in
argininosuccinic aciduria.
2. The effects of combinatorial therapy with a low-dose of arginine and sodium
phenylbutyrate vs. a high-dose of arginine alone on hepatic function tests in
argininosuccinic aciduria were compared.
3. We show that treatment with high-dose of arginine leads to increase in plasma
argininosuccinate and hepatic aminotransferases.
4. A lower dose of arginine that is sufficient to normalize plasma arginine levels,
combined with nitrogen scavenging therapy should be considered as an
alternative therapeutic option for chronic treatment, especially in patients with
hepatic disease.
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Figure 1. Study design
A. Illustrative example of the depicting the study design and study procedures. In this
depiction, the subject was randomized to high-dose arginine as the first treatment arm. (PAA
– plasma amino acids, BUN – blood urea nitrogen, PT-prothrombin time, PTT- partial
thromboplastin time, INR-International normalized ratio) B. Plasma PAGN levels are
elevated in patients while on the LDA arm due to conjugation of phenylbutyrate with
glutamine to form PAGN. Treatment with high-dose of arginine leads to increase in plasma
arginine levels (** P<0.001). C. Short-term nitrogen balance was comparable in both
treatment arms as evidenced by normal plasma ammonia and glutamine levels (ns - not
significant). The box plots depict the 25th and 75th centile along with the median whereas
the error bars depict the 5th and 95th centile.
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Figure 2. Effect of the two treatment arms on metabolite fluxes and argininosuccinate levels
The arginine, citrulline (A) and the urea (B, left panel) fluxes are increased with the high-
dose arginine treatment while glutamine flux (B, right panel) is comparable in both arms
(**P<0.001, ns - not significant). C. Treatment with the high-dose of arginine results in
increased plasma argininosuccinate (P<0.05). Each data-point on depicts the mean of two
values measured on days 6 and 7.
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Figure 3. Effect of the two treatment arms on aspartate and alanine aminotransferases
A. Treatment with the high-dose of arginine leads to increase in plasma AST and ALT. The
increased AST levels on HDA arm were statistically significant (P=0.002). Each data-point
on the graph depicts the mean of two values measured on days 6 and 7. B. Linear regression
using GEE and Spearman rank correlation found a significant relationship between plasma
argininosuccinate and AST (partial η2 = 0.635, P<0.001; r2=0.568) and ALT levels (partial
η2 = 0.794, P<0.001; r2=0.474).
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Figure 4. Effect of two treatment arms on hepatic synthetic functions
A. Coagulation parameters evaluating the extrinsic and the intrinsic pathway show no
differences between the two arms. B. Plasma levels of coagulation factors are similar with
both treatments.
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Figure 5. Stratified analysis of aminotransferase levels in subjects with elevations of AST and
ALT
The subset of patients with elevation of aminotransferases on at least one arm of the study
had significant reduction of ALT (*P<0.05) and AST (*P<0.05) with low-dose of arginine
as compared to those who had normal aminotransferase levels on both arms of the study.
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